★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
◀ BACK TO FEED
NEWS★ LIFE SCIENCES / BIOTECHNOV 12, 2026

Neurosterix adds Karuna veterans as it details $105m financing

Neurosterix named its Series B investors and added Andrew Miller and Stephen Brannan to senior roles.

Neurosterix adds Karuna veterans as it details $105m financing

A biotech financing becomes more informative when the investors and clinical-development team are visible. Neurosterix has added that detail.

What happened

On 12 November, Neurosterix identified RTW Investments as lead investor in its $105m Series B and named participants including GV and Janus Henderson. It also appointed Karuna founder Andrew Miller as executive chair and Stephen Brannan as clinical advisory board chair. Addex had disclosed the financing on 11 November. Funding supports Phase 2 development of NTX-253 for schizophrenia.

Why it matters

The appointments bring neuropsychiatric drug-development experience into roles that can influence study design and development strategy. Naming the investors adds information about the specialist capital supporting the programme.

The bigger picture

Biotech progress depends on capital, clinical planning and experienced teams working together. Here, the new development is the expanded investor and leadership disclosure around an existing financing.

#NEUROSTERIX#NEUROPSYCHIATRY#DRUG DEVELOPMENT